Clik here to view.
AMR and Europe - What Happened?
Like many of you, I recently received a notification from John Rex and Kevin Outterson regarding the fact that many recently approved antibiotics will not be marketed in Europe. At first glance, I...
View ArticleClik here to view.
Introducing the Pasteur Act for AMR
WARNING - This is long! Today, I discuss the Pasteur Act, a new bill proposed in the US Senate by senators Bennet and Young, with Ryan Cirz. You can find a summary of the bill here and the full bill...
View ArticleClik here to view.
The Pasteur Act - A View from Industry
Chris Burns Evan LohWe will continue our discussion of the Pasteur Act as proposed by Senators Bennet and Young. Today I discuss the bill with two biotech CEOs, Chris Burns of Venatorx and Evan Loh of...
View ArticleClik here to view.
AMR - a Holistic Approach
A very important report on the state of antibiotic use and resistance globally has just been release by The Center for Disease Dynamics, Economics & Policy (CDDEP). Before delving into this...
View ArticleClik here to view.
Covid vaccines compared to AMR
I never dreamed this would be possible. Of course, so many things are possible today that I thought were impossible that I’m almost embarrassed to admit it (but I have no pride). Twenty-five years ago...
View ArticleClik here to view.
Pull Incentives and AMR - Is Europe up to the Task?
I have been saying for years that for a pull incentive to actually function as an incentive, it must be large enough to motivate investors and large pharma to get back into antibiotic R&D. This...
View ArticleClik here to view.
The Pew Trust Analysis of the Antibacterial Pipeline
The Pew Charitable Trust just posted their analysis of the antibacterial pipeline. They provide two separate analyses, one for antibiotics and the other for non-traditional therapies. I will ignore...
View ArticleClik here to view.
Pull American - Why Not?
In a sleepy moment I had an inspiration. Funding a pull incentive for antibiotic R&D in the US (like a market entry reward for example) would be more attractive to our representatives in congress...
View ArticleClik here to view.
Antibiotic Strategies for Success - A Bridge to Nowhere?
This blog was inspired by a recent conversation with a CEO of a clinical phase antibiotic biotech. Among other things, we pursued a discussion of various strategies that companies developing...
View ArticleEmpiric broad spectrum antimicrobial therapy is here to stay.
Recent discussions on the economics of innovation in rapid diagnostic testing for bacterial infections in the hospital setting have inspired me to once again take pen (keyboard) in hand. In most of...
View ArticleClik here to view.
Europe, Antibacterials, Pull Incentives and Access
Without a significant pull incentive, our pipeline of new antibacterials is doomed. This must be our top priority. If a significant pull incentive for new antibacterial research and development is...
View ArticleClik here to view.
Pull Incentives at ASM/ESCMID
On a personal note, as I grow older, I find I am likely to be more dependent on physicians and caregivers. I am grateful to have a truly talented, kind and smart team of physicians, nurses, family...
View ArticleClik here to view.
Pull Incentives for AMR - Where is Biden?
This will be a short note . . .We are about to dedicate an entire ASM/ESCMID session to planning for the implementation of forthcoming pull incentives. We do this because we all agree that without...
View ArticleClik here to view.
Covid - Thank you to industry - Please do the same for AMR.
To all those who are skeptical because they worry that a government sponsored investment in the broken antibiotic marketplace is a give-away to the pharmaceutical industry, I have one word for you –...
View ArticleClik here to view.
To have functioning public health in the US, we must first have national...
A recent report by the US Government Accountability Office (GAO) highlights risks associated with the response to pandemics at the US Department for Health and Human Services (HHS) (1,2). These...
View ArticleEntasis, Antibiotics and the Dodo
And again! Entasis Therapeutics has been struggling in the public marketplace. There is certainly a risk that it will be going the way of Melinta, Achaogen, Tetraphase and the Dodo bird. Investors...
View ArticleClik here to view.
The Future of Antibiotics
Spoiler alert – get out the anti-depressants. Before I get to the issue at hand, I need to share with you my recent experience posting blogs on Google’s Blogger – something I’ve been happily doing,...
View ArticlePull Incentives for Antibiotic R&D and Private Investment
John Rex (thank you) just sent out an email highlighting a paper emanating from the Milliken Institute on how private investment could augment government sponsored pull incentives for antibiotic...
View ArticleClik here to view.
ASM Microbe - Antimicrobial Agents and Resistance
Guest BloggerKrisztina M. Papp-Wallace Introducing the ASM Microbe 2022 Antimicrobial Agents and Resistance Program Dear AAR community, As an AAR track member of the ASM Microbe 2022 program...
View ArticleClik here to view.
Why Antibiotics Don't Work - Implications for Clinical Trial Design
I want to discuss the idea of superiority trials for antibiotics and some of the issues that many experienced researchers fail to consider when thinking about this topic. I am grateful to George...
View Article
